nct_id: NCT06852222
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2025-02-28'
study_start_date: '2025-06-04'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: Azacitidine (AZA)'
  - drug_name: 'Drug: Placebo'
  - drug_name: 'Drug: Bleximenib'
  - drug_name: 'Drug: Venetoclax (VEN)'
long_title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Bleximenib,
  Venetoclax and Azacitidine for the Treatment of Participants With Newly Diagnosed
  Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations Who Are
  Ineligible for Intensive Chemotherapy
last_updated: '2025-11-07'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE3
principal_investigator: NA
principal_investigator_institution: Janssen Research & Development, LLC
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 600
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion criteria:'
- '* Be 18 years of age or older at the time of informed consent'
- '* Previously untreated lysine N-methyltransferase 2A gene rearranged (KMT2Ar) or
  nucleophosmin 1 gene mutated (NPM1m) acute myeloid leukemia (AML) with greater than
  or equal to (\> or =) 10% bone marrow blasts per 2022 international Consensus Classification
  criteria'
- '* Ineligible for intensive chemotherapy based on the following criteria: a) \>=
  75 years of age and ineligible per physician''s discretion, with Eastern Cooperative
  Oncology Group (ECOG) performance status of 0-2, b) \>=18 to \<75 years of age with
  \>= 1 of the following comorbidities: i) ECOG performance status of 2, ii) Severe
  cardiac disorder, iii) Severe pulmonary disorder, iv) Renal impairment, v) Moderate
  hepatic impairment vi) Comorbidity that, in the investigator''s opinion, makes the
  participant unsuitable for intensive chemotherapy, which must be documented before
  enrollment as defined in the protocol. Ineligibility for intensive chemotherapy
  should be explicitly approved by a multidisciplinary team in countries in which
  this process is standard of care'
- '* Participants must have adequate hepatic and renal function'
- '* A female participant must agree not to be pregnant, breast-feed, plan to become
  pregnant and use protocol-specified contraception while enrolled in this study and
  for 6 months after the last dose of study treatment'
- '* A male participant must agree to use protocol-specified contraception while enrolled
  in this study for at least 90 days after the last dose of study treatment'
- '* Must sign an informed consent form indicating that the participant understands
  the purpose of, and procedures required for, the study and is willing to participate
  in the study'
- 'Exclusion criteria:'
- '* Diagnosis of acute promyelocytic leukemia (APL)'
- '* Known active leukemic involvement of the central nervous system (CNS)'
- '* Recipient of solid organ transplant'
- '* Any cardiac disorders such as heart attack, uncontrolled/unstable chest pain,
  congestive heart failure, uncontrolled or symptomatic irregular heartbeat, blockage
  of a blood vessel to brain, or transient ischemic (decreased oxygen in tissue) attack
  within 6 months of randomization'
- '* Active infectious hepatitis'
- '* Live, attenuated vaccine within 4 weeks of randomization'
- '* Known allergies, hypersensitivity, or intolerance of bleximenib, azacitidine,
  or venetoclax excipients'
short_title: A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants
  With Newly Diagnosed Acute Myeloid Leukemia (AML)
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Janssen Research & Development, LLC
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+
  Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment
  of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutation
  in the NPM1 or KMT2A gene.
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: 'Arm A: Bleximenib and Venetoclax (VEN) + Azacitidine (AZA)'
      arm_internal_id: 0
      arm_description: Participants with acute myeloid leukemia (AML) will receive
        bleximenib in combination with venetoclax (VEN) and azacitidine (AZA) for
        28-days treatment cycles and treatment will continue until progression or
        unacceptable toxicity.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Bleximenib'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Venetoclax (VEN)'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Azacitidine (AZA)'
        level_internal_id: 2
        level_suspended: N
    - arm_code: 'Arm B: Placebo and Venetoclax (VEN) + Azacitidine (AZA)'
      arm_internal_id: 1
      arm_description: Participants with AML will receive placebo in combination with
        VEN and AZA for 28-days treatment cycles, and treatment will continue until
        progression or unacceptable toxicity.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Venetoclax (VEN)'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Azacitidine (AZA)'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Placebo'
        level_internal_id: 2
        level_suspended: N
    match:
    - clinical:
        age_numerical: '>=18'
        disease_status:
        - Untreated
        oncotree_primary_diagnosis: Myeloid Neoplasm
